Characterization of genomic breakpoints in MLL and CBP in leukemia patients with t(11;16)

Yanming Zhang, Nancy Zeleznik-Le, Neelmini Emmanuel, Nimanthi Jayathilaka, Jianjun Chen, Pamela Strissel, Reiner Strick, Loretta Li, Mary Beth Neilly, Tomohiko Taki, Yasuhide Hayashi, Yasuhiko Kaneko, Brigitte Schlegelberger, Janet D. Rowley*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


The recurring chromosome translocation t(11;16)(q23;p13) is detected in leukemia patients, virtually all of whom have received previous chemotherapy with topoisomerase (topo) II inhibitors. In the t(11;16), 3′ CBP, on 16p13, is fused to 5′ MLL, on 11q23, resulting in an MLL-CBP fusion gene that plays an important role in leukemogenesis. In this study, we cloned genomic breakpoints of the MLL and CBP genes in the 1(11;16) in the SN-1 cell line and in five patients with therapy-related leukemia, all of whom had received topo II inhibitors for previous tumors. In all patients except one, both the genomic MLL-CBP and the reciprocal fusions were cloned. Genomic breakpoints in MLL occurred in the 8.3-kb breakpoint cluster region in all patients, whereas the breakpoints in CBP clustered in an 8.2-kb region of intron 3 in four patients. Genomic breakpoints in MLL occurred in intron 11 near the topo II cleavage site in the SN-1 cell line and in one patient, and they were close to LINE repetitive sequences in two other patients. In the remaining two patients, genomic breakpoints were in intron 9 in Alu repeats. Genomic breakpoints in CBP occurred in and around Alu repeats in one and two patients, respectively. In two patients, the breaks were near LINE repetitive sequences, suggesting that repetitive DNA sequences may play a role. No specific recombination motifs were identified at or near the breakpoint junctions. No topo II cleavage sites were detected in introns 2 and 3 of CBP. However, there were deletions and duplications at the breakpoints in both MLL and C6P and microhomologies or nontemplated nucleotides at most of the genomic fusion junctions, suggesting that a nonhomologous end-joining repair mechanism was involved in the t(11;16).

Original languageEnglish (US)
Pages (from-to)257-265
Number of pages9
JournalGenes Chromosomes and Cancer
Issue number3
StatePublished - Nov 2004

ASJC Scopus subject areas

  • Genetics
  • Cancer Research


Dive into the research topics of 'Characterization of genomic breakpoints in MLL and CBP in leukemia patients with t(11;16)'. Together they form a unique fingerprint.

Cite this